⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Table S3 from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma

Kevin Christian Montecillo Gulay Xinlian Zhang Vasiliki Pantazopoulou Jay Patel Edgar Esparza Deepa Sheik Pran Babu Satoshi Ogawa Jonathan Weitz Isabella Ng Evangeline Mose Minya Pu Dannielle D. Engle Andrew M. Lowy Hervé Tiriac

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Table S3. Results of RPPA and transcriptomic analyses.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gulay et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587523202 https://doi.org/10.1158/0008-5472.27028363

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S3 from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma2024
2Table S1 from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma2024
3Table S1 from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma2024
4Table S2 from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma2024
5Table S2 from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma2024

More related papers

Data from Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma2024
Supplementary Figure S9 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer2024
Supplementary Figure S9 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer2024